Researchers developed a modular engineering approach to redirect adeno-associated virus (AAV) vectors toward neuroblastoma cells by coupling the viral platform with a targeting antibody. The work focuses on changing AAV tropism while maintaining the delivery utility of the platform. For translational drug developers, the most important near-term signals will be whether target engagement improves tumor uptake and whether on-target delivery affects biodistribution, immunogenicity, and safety. The approach also hints at a broader strategy: antibody-coupled AAV for cell-type-specific oncology targeting. Further preclinical detail will be needed around tumor-to-normal tissue ratios, dose-limiting toxicities, and persistence/efficacy in relevant neuroblastoma models before considering expansion toward IND-enabling studies.